Tumor immune microenvironment of EGFR-mutant non-small-cell lung cancer and its impact on therapeutic efficacy

被引：4
|
作者：
Matsumoto, Yoshiya [1 ,2 ]
Koh, Yasuhiro [2 ]
机构：
[1] Osaka City Univ, Grad Sch Med, Dept Resp Med, Osaka, Japan
[2] Wakayama Med Univ, Internal Med 3, Wakayama, Japan
来源：
IMMUNOTHERAPY | 2020年 / 12卷 / 07期
关键词：
epidermal growth factor receptor; non-small-cell lung cancer; tumor microenvironment; tumor mutational burden; PD-L1; EXPRESSION; MUTATION INCIDENCE; OPEN-LABEL; PHASE IB; DOCETAXEL; NIVOLUMAB; ATEZOLIZUMAB; BLOCKADE; INFILTRATION; CHEMOTHERAPY;
D O I：
10.2217/imt-2019-0213
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
下载
收藏
页码：431 / 438
页数：8
相关论文
共 50 条
  • [1] Treatment choice in EGFR-mutant non-small-cell lung cancer
    Brueckl, Wolfgang M.
    LANCET ONCOLOGY, 2017, 18 (11): : 1425 - 1426
  • [2] Spontaneously expectorated EGFR-mutant non-small-cell lung cancer
    Sumi, Toshiyuki
    Terai, Kotomi
    Chiba, Hirofumi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (11) : 1094 - 1095
  • [3] The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer
    Boussageon, Maxime
    Swalduz, Aurelie
    Perol, Maurice
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (10) : 1071 - 1080
  • [4] The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
    Fei Zhou
    Haoyue Guo
    Yang Xia
    Xiuning Le
    Daniel S. W. Tan
    Suresh S. Ramalingam
    Caicun Zhou
    Nature Reviews Clinical Oncology, 2025, 22 (2) : 95 - 116
  • [5] Brain metastases in patients with EGFR-mutant non-small-cell lung cancer
    Rosell, Rafael
    Karachaliou, Niki
    LANCET RESPIRATORY MEDICINE, 2017, 5 (09): : 669 - 671
  • [6] Circulating tumour DNA in EGFR-mutant non-small-cell lung cancer
    Cabanero, M.
    Tsao, M. S.
    CURRENT ONCOLOGY, 2018, 25 : S38 - S44
  • [7] Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer
    Wu, Fang
    Liu, Xianling
    Ma, Jin-an
    Gao, Yawen
    Hu, Chunhong
    LANCET ONCOLOGY, 2018, 19 (03): : E124 - E124
  • [8] Targeting MET amplification in EGFR-mutant non-small-cell lung cancer
    Rosell, Rafael
    Chaib, Imane
    Santarpia, Mariacarmela
    LANCET RESPIRATORY MEDICINE, 2020, 8 (11): : 1068 - 1070
  • [9] Minimal residual disease in EGFR-mutant non-small-cell lung cancer
    Bain, Nathan T. T.
    Wang, Yang
    Arulananda, Surein
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [10] Tumor Microenvironment Modulation by Neoadjuvant Erlotinib Therapy and Its Clinical Impact on Operable EGFR-Mutant Non-Small Cell Lung Cancer
    Ahn, Beung-Chul
    Park, Charny
    Kim, Moon Soo
    Lee, Jong Mog
    Choi, Jin Ho
    Kim, Hyae Young
    Lee, Geon Kook
    Yu, Namhee
    Lee, Youngjoo
    Han, Ji-Youn
    CANCER RESEARCH AND TREATMENT, 2024, 56 (01): : 70 - 80
12345